Guardion Health Sciences (Guardion Health Sciences) COGS-to-Revenue : 0.61 (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Guardion Health Sciences COGS-to-Revenue?

Guardion Health Sciences's Cost of Goods Sold for the three months ended in Mar. 2024 was $1.82 Mil. Its Revenue for the three months ended in Mar. 2024 was $3.00 Mil.

Guardion Health Sciences's COGS to Revenue for the three months ended in Mar. 2024 was 0.61.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Guardion Health Sciences's Gross Margin % for the three months ended in Mar. 2024 was 39.30%.

Guardion Health Sciences COGS-to-Revenue Historical Data

The historical data trend for Guardion Health Sciences's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guardion Health Sciences COGS-to-Revenue Chart

Guardion Health Sciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.38

1.03

0.57

0.59

0.56

Guardion Health Sciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
COGS-to-Revenue	Get a 7-Day Free Trial															0.58	0.55	0.56	0.54	0.61

Guardion Health Sciences COGS-to-Revenue Calculation

Guardion Health Sciences's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	6.854	/	12.249
	=	0.56

Guardion Health Sciences's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	1.821	/	3
	=	0.61

Guardion Health Sciences (NAS:GHSI) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Guardion Health Sciences's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	1.821 / 3
	=	39.30 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Guardion Health Sciences COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Guardion Health Sciences's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Guardion Health Sciences (Guardion Health Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Guardion Health Sciences Inc (NAS:GHSI) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

0QTA:Germany

Address

2925 Richmond Avenue, Suite 1200, Houston, TX, USA, 77098

Website

https://www.guardionhealth.com

Guardion Health Sciences Inc is a specialty health sciences company formed to develop, formulate and distribute condition-specific medical foods with an initial medical food product. The company's Medical Foods include Lumega-Z and GlaucoCetin; Medical Devices include Mapcat SF, VectorVision, CSV-1000 and CSV-2000; Nutraceuticals include ImmuneSF.

Executives

Katharine Joan Cox	officer: Chief Accounting Officer	2925 RICHMOND AVENUE, SUITE 1200, HOUSTON TX 77098
Janet Hall	officer: CEO & President	2925 RICHMOND AVENUE, SUITE 1200, HOUSTON TX 77098
Bradley Louis Radoff	10 percent owner	2727 KIRBY DRIVE, UNIT 29L, HOUSTON TX 77098
Family Foundation Radoff	other: See Footnote 1	2727 KIRBY DRIVE, UNIT 29L, HOUSTON TX 77098
Michaela Griggs	director	2925 RICHMOND AVENUE, SUITE 1200, HOUSTON TX 77098
Bret Scholtes	director, officer: Chief Executive Officer	2105 CITY WEST BLVD., SUITE 500, HOUSTON TX 77042
Donald A Gagliano	director	131 CARDINAL AVE, SAN ANTONIO TX 78209
Jeffrey S Benjamin	officer: Chief Accounting Officer	3885 CRESTWOOD PARKWAY, SUITE 550, DULUTH GA 30096
Craig Sheehan	officer: Chief Commercial Officer	15150 AVENUE OF SCIENCE, SUITE 200, SAN DIEGO CA 92128
Andrew C Schmidt	officer: Chief Financial Officer	1700 CARNEGIE AVE, SUITE 100, SANTA ANA CA 92705
Kelly Anderson	director	C/O TOMI ENVIRONMENTAL SOLUTIONS, INC., 9454 WILSHIRE BLVD., R-1, BEVERLY HILLS CA 90212
David W Evans	director, officer: Chief Scientific Officer	4141 JUTLAND DRIVE, SUITE 215, SAN DIEGO CA 92117
Tamara A Evans	10 percent owner	4141 JUTLAND DRIVE, SUITE 215, SAN DIEGO CA 92117
Vincent J Roth	officer: General Counsel and Secretary	15150 AVENUE OF SCIENCE, SUITE 200, SAN DIEGO CA 92128
Robert N Weingarten	director	5439 LOCKHURST DRIVE, WOODLAND HILLS CA 91367